| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 53.81 | 1592.1% | 363.5% |
| Total Income | 53.81 | 1592.1% | 363.5% |
| Expenditure | 39.74 | 10.0% | 10.7% |
| PBT | 15.87 | 140.9% | 154.5% |
| Net Profit | 15.88 | 140.9% | 154.4% |
| OPM | 26.15% | ||
| NPM | 29.52% | ||
| EPS | 0.14 | 140.0% | 151.8% |
Tango Therapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 8:10 am
Summary
Tango Therapeutics reported financial results for the third quarter ended September 30, 2025. Collaboration revenue was $53.8 million for the quarter, compared to $11.6 million for the same period in 2024. The company's cash, cash equivalents, and marketable securities totaled $152.8 million as of September 30, 2025. Net income for the quarter was $15.9 million, or $0.14 per share (basic) and $0.13 per share (diluted).
Key Highlights
- 1
Tango Therapeutics reported collaboration revenue of $53.8 million for the three months ended September 30, 2025, compared to $11.6 million for the same period in 2024.
- 2
The company held $152.8 million in cash, cash equivalents and marketable securities as of September 30, 2025.
- 3
Net income for the three months ended September 30, 2025 was $15.9 million, or $0.14 per share (basic) and $0.13 per share (diluted).
- 4
Gross proceeds of $225 million from October 2025 financing extends cash runway into 2028.
- 5
Vopimetostat data update showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) of 7.2 months.
- 6
49% ORR and mPFS 9.1 months in histology selective cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity.
Management Comments
Barbara Weber
M.D.
“We are wrapping up 2025 with significant momentum, supported by our recent disclosure of vopimetostat clinical data, supporting the potential of this compound to be a turning point for treatment of multiple difficult-to-treat MTAP-del cancers, beginning with pancreatic cancer." “The data we presented support our planned pivotal trial in 2L MTAP-del pancreatic cancer with an anticipated study start in 2026. Our ongoing study of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors is also progressing well and we look forward to sharing an update from that study in 2026. Our clinical development plans are supported by our strong balance sheet, reinforced by our recent $225 million financing, which extends our cash runway into 2028. Additionally, we expect a strong cadence of value creating milestones in 2026.”
Informational and educational content only. Not investment advice.